Search Results

You are looking at 1 - 10 of 60 items for :

  • Framingham Risk Score x
Clear All
Open access

Snežana Jovičić, Svetlana Ignjatović and Nada Majkić-Singh

-10. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24 : 987-1003. National Cholesterol Education Program. Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death). Topol EJ, Lauer MS. The rudimentary phase of personalised medicine: coronary risk scores. Lancet

Open access

Alin Albai, Mirela Frandeș, Ramona Luminița Sandu, Gabriel Spoială, Flavia Hristodorescu, Bogdan Timar and Romulus Timar

, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24: 987-1003, 2003. 6. D’Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743-753, 2008. 7. Centers for Disease Control and Prevention . National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for

Open access

Matjaz Vrtovec, Ajda Anzic, Irena Preloznik Zupan, Katja Zaletel and Ales Blinc

significant number of patients with ET had a high calcium score not predicted by the Framingham risk equation for coronary disease ( Table 6 , Figure 2 ). While a significant correlation between the Framingham CHD risk and the Agatston was found for control subjects (r = 0.577, p < 0.001), no significant correlation was found fort the patients with ET (r = 0.197, p =0.223). Figure 2 Correlation of the Framingham coronary heart disease (CHD) risk and coronary calcification (Agatston score). While a significant Pearson correlation between the Framingham CHD risk and

Open access

Vaia D. Raikou

coronary heart disease is the Framingham risk score (FRS). According to the National Institutes of Health, the patients having chronic kidney disease are considered as having a coronary heart disease risk equivalent, meaning that they are primarily patients with a 10-year risk for myocardial infarction or coronary death >20%, despite without known coronary heart disease. [ 8 ] Metabolic acidosis, a common condition and an important manifestation of the late stage of chronic kidney disease, leads to clinically significant consequences, including bone disease disorders

Open access

Sakunee Khankham, Leena Chularojanamontri, Chanisada Wongpraparut, Narumol Silpa-archa, Nuttaporn Janyong and Prin Vathesatogkit

Coronary artery disease (CAD) has become an important cause of death and comorbid disease among the general population. Several assessment tools have been developed to predict the 10-year risk of developing CAD and coronary death. The Framingham Risk Score (FRS), which was developed in 1998, is probably the most well-known [ 1 ]. The FRS is validated in the U.S. population and performs well when applied to other populations with a similarly high background risk of CAD. However, application of the FRS overestimated the risk of CAD in cohorts in Europe, Asia, and

Open access

Snežana Jovičić

inhibits three steps in the formation of mildly oxidized low density lipoprotein. J Lipid Res 2000; 41: 1481-508. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996; 7: 209-16. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994

Open access

Nevena Eremić and Mirjana Đerić

Cholesterol Education Program Adult Treatment Panel III Guidelines. JACC 2004; 44 (3): 720-32. National Heart Lung and Blood Institute. Framingham Heart Study. Sarti C, Gallagher J. The metabolic syndrome. J Diabetes Complicat 2006; 20 (2): 121-32. Assman G, Cullen P, Shulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study

Open access

Carasca Cosmin, Muresan Vasile Adrian, Tilea Ioan, Magdas Annamaria, Carasca Emilian and Incze Alexandru

References 1. Murabito JM, D’Agostino RB, Silbershatz H, Wilson PWF. Intermittent Claudication - A Risk Profile From The Framingham Heart Study. Circulation, 1997;96:44-49. 2. Khan S, Flather M, Mister R et al. Characteristics and Treatments of Patients with Peripheral Arterial Disease Referred to UK Vascular Clinics: Results of a Prospective Registry. European Journal of Vascular and Endovascular Surgery, 2007;33:4:442–450. 3. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with

Open access

Daria Pašalić and Natalija Marinković

References 1. Dandona S, Roberts R. The role of genetic risk factors in coronary artery disease. Curr Cardiol Rep 2014;16:479. doi: 10.1007/s11886-014-0479-2 2. Sayols-Baixeras S, Lluís-Ganella C, Lucas G, Elosua R. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet 2014;7:15-32. doi: 10.2147/TACG.S35301 3. Marinković N, Pašalić D, Potočki S. Polymorphisms of genes i n v o l v e d i n p o l y c y c l i c a r o m a t i c hydrocarbons

Open access

R. Gancheva, A. Kundurdjiev, T. Kundurdjiev and Zl. Kolarov

REFERENCES 1. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009; 61:885-892. 2. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyper-uricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125(7):679-687. 3. Lai HM, Chen CJ, Su BY, et al. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences. Rheumatology 2012; 51(4):715-20. 4. Carnethon MR, Fortmann SP, Palaniappan L, et al. Risk